Biogen outlines 10M-patient opportunity for Alzheimer's drug in US

Biogen outlines 10M-patient opportunity for Alzheimer's drug in US

Source: 
Biopharma Reporter
snippet: 

Biogen has estimated 10 million patients in the US are suitable for treatment with its Alzheimerâs disease candidate aducanumab, setting it up to generate blockbuster sales if it wins approval.